Loading...
TARA logo

Protara Therapeutics, Inc.NasdaqGM:TARA 주식 보고서

시가총액 US$279.3m
주가
US$4.92
US$26.57
81.5% 저평가 내재 할인율
1Y57.2%
7D-3.5%
1D
포트폴리오 가치
​
보기

Protara Therapeutics, Inc.

NasdaqGM:TARA 주식 리포트

시가총액: US$279.3m

Protara Therapeutics (TARA) 주식 개요

임상 단계의 바이오 제약 회사인 프로타라 테라퓨틱스는 암과 희귀 질환 치료를 위한 혁신적 치료법을 개발하는 데 주력하고 있습니다. 자세히 보기

TARA 펀더멘털 분석
스노우플레이크 점수
가치 평가5/6
미래 성장2/6
과거 실적0/6
재무 건전성6/6
배당0/6

강점

공정 가치 추정치보다 낮은 97.6% 에서 거래

수익은 연간 65.99% 증가할 것으로 예상됩니다.

분석가들은 주가가 440.1% 상승할 것이라는 데 동의합니다.

위험 분석

수익이 USD$1m 미만입니다($0)

지난 1년 동안 주주가 크게 희석되었습니다.

지난 3개월 동안 주가 변동성이 US 시장과 비교해 높았습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.


TARA Community Fair Values

Create Narrative

See what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Protara Therapeutics, Inc. 경쟁사

가격 이력 및 성과

Protara Therapeutics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$4.92
52주 최고가US$7.82
52주 최저가US$2.77
베타1.53
1개월 변동-9.06%
3개월 변동-28.07%
1년 변동57.19%
3년 변동66.78%
5년 변동-48.10%
IPO 이후 변동-83.60%

최근 뉴스 및 업데이트

Recent updates

Seeking Alpha • Dec 04

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Summary Protara Therapeutics maintains strong momentum with TARA-002, showing durable, high complete response rates in NMIBC and promising efficacy in lymphatic malformations. TARA-002’s 6-month complete response rate of 69% in BCG-naive NMIBC patients and 100% clinical success in lymphatic malformations reinforce its competitive positioning. With over two years of cash runway, TARA is well-capitalized to reach pivotal regulatory and clinical milestones without near-term dilution risk. I maintain a 'Buy' rating on TARA, though with tempered conviction, as positive data and market opportunity are balanced by evolving competition and volatility. Read the full article on Seeking Alpha
분석 기사 • Jul 10

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Mar 28

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Summary TARA’s leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable results in NMIBC, with a notable 72% complete response rate at six months. TARA’s pipeline also has IV Choline, which could target unmet needs in patients requiring parenteral nutrition, and it has no other FDA-approved alternatives. I also believe their cash reserves and recent raise secure their runway, at least until 2027. So, even though TARA remains a relatively speculative microcap, I believe it trades at a compelling valuation in light of its potential. So I rate it a “Buy” at these levels. Read the full article on Seeking Alpha
분석 기사 • Mar 07

We're Hopeful That Protara Therapeutics (NASDAQ:TARA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 10

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Summary Initial data from the phase 2 ADVANCED-2 study, using TARA-002 for the treatment of patients with non-muscle invasive bladder cancer, is expected by mid-2025. The global bladder cancer market size is expected to reach $5.4 billion by 2034. Initial results from the phase 2 STARBORN-1 study, using TARA-002 for the treatment of pediatric patients with macroystic and mixed cystic LMs, are expected in the 1st half of 2025. Dosing of first patients in phase 3 THRIVE-3 study, using IV choline chloride for parenteral support patients, are expected in Q1 of 2025. The company had $81.5 million in cash as of September 30th of 2024; Despite the cash runway, management chose to raise approximately $100 million through an underwritten public offering. Read the full article on Seeking Alpha
분석 기사 • Nov 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Protara Therapeutics...
분석 기사 • Aug 08

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Feb 22

Protara: A Bombed Out Biotech With A Very Positive Skew

Summary Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas. The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is trading below its cash value, presenting a potential undervaluation opportunity if its phase 2 trials are successful. Read the full article on Seeking Alpha
분석 기사 • Dec 16

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Apr 22

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

The Prognosis For Protara Therapeutics

Summary We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. The stock has seen some small insider buying throughout 2022 and the shares sell for less than 50% of the company's net cash on the balance sheet. An investment analysis follows in the paragraphs below. Men are never convinced of your reasons, of your sincerity, of the seriousness of your sufferings, except by your death. So long as you are alive, your case is doubtful; you have a right only to their skepticism.”― Albert Camus We took our first look at Protara Therapeutics (TARA) back in the first quarter of 2021. No one on Seeking Alpha has provided coverage on the company since. Given I get an occasional question around Protara, today we are going to circle back on this small biopharma concern. An updated analysis follows below. Seeking Alpha Company Overview: Protara Therapeutics was formed when Proteon Therapeutics merged with privately held ArTara Therapeutics in late 2019. The company is based in New York City and is focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs. The stock currently trades around $3.50 a share and has an approximate market capitalization of $40 million. March Company Presentation The company's pipeline consists mainly of one key compound in development. Protara's lead pipeline asset is TARA-002. It is in development for the treatment of lymphatic malformations [LMs] and non-muscle invasive bladder cancer (NMIBC). It has a Rare Pediatric Disease designation for LMs. March Company Presentation The company received preliminary guidance regarding a development path for TARA-002 in lymphatic malformations in the first quarter of this year from the FDA. March Company Presentation Management's plan is to initiate a Phase 2 clinical trial in this indication, subject to alignment with FDA on the clinical trial protocol. LMs are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth. March Company Presentation The first patient was dosed in Phase 1 trial evaluating TARA-002 to treat NMIBC in the first quarter of 2022. NMIBC represents 80% of all bladder cancer, which is the sixth most frequent time of cancer in the world. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. March Company Presentation When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan and Taiwan. March Company Presentation The company is also doing a prospective study to enhance its understanding of the incidence of Intestinal Failure Associated Liver Disease or IFALD in patients dependent on parenteral nutrition that remains ongoing. The company did get a key patent for this potential IV Choline Chloride program in April of this year. This candidate is an investigational, intravenous (IV) phospholipid substrate replacement therapy. There doesn't seem to be much movement in this program since we last looked at Protara in February of 2021. March Company Presentation Analyst Commentary & Balance Sheet: The company gets sparse commentary on Wall Street. In 2022, Oppenheimer ($32 price target), H.C. Wainwright ($23 price target) and Ladenberg Thalmann ($32 price target) have maintained Buy ratings on the stock. These are the only analyst firms I can find that have chimed in around Protara so far this year. Approximately two percent of the outstanding float in the shares are currently held short. At the end of the second quarter, the company had nearly $100 million of cash and marketable securities on its balance sheet against no long term debt. Management has guided that this cash balance is sufficient to fund all planned activities until mid-2024. The company had a net loss of $8.5 million in 2Q2022.
분석 기사 • Sep 12

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Mar 21

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Dec 06

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

주주 수익률

TARAUS BiotechsUS 시장
7D-3.5%1.2%1.0%
1Y57.2%34.9%28.7%

수익률 대 산업: TARA은 지난 1년 동안 34.9%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: TARA은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is TARA's price volatile compared to industry and market?
TARA volatility
TARA Average Weekly Movement11.7%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

안정적인 주가: TARA의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: TARA의 주간 변동성(12%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
n/a46Jesse Sheffermanwww.protaratx.com

임상 단계의 바이오 제약 회사인 프로타라 테라퓨틱스는 암과 희귀 질환 치료를 위한 혁신적 치료법을 개발하는 데 주력하고 있습니다. 이 회사의 주요 프로그램은 비근육 침습성 방광암 및 림프 기형 치료를 위한 임상 2상 시험 중인 연구용 세포 치료제인 TARA-002입니다. 또한 비경구 영양 및 수액을 투여받는 환자를 위한 연구용 인지질 기질 대체 요법인 정맥 내 염화콜린을 개발 중입니다.

Protara Therapeutics, Inc. 기초 지표 요약

Protara Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
TARA 기초 통계
시가총액US$279.34m
순이익 (TTM)-US$63.31m
매출 (TTM)n/a
0.0x
주가매출비율(P/S)
-4.4x
주가수익비율(P/E)

TARA는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
TARA 손익계산서 (TTM)
매출US$0
매출원가US$0
총이익US$0
기타 비용US$63.31m
순이익-US$63.31m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)-1.13
총이익률0.00%
순이익률0.00%
부채/자본 비율0%

TARA의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 14:03
종가2026/05/22 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Protara Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Li Wang WatsekCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.